Revenue climbed from about $594M in 2025Q1 to roughly $1.5B in 2026Q3 with gross margins of 75% to 88%, but operating margin swung from -17.7% to 29.5%, indicating that gross profit strength has not yet translated into stable bottom-line results.
Alnylam Pharmaceuticals, Inc. (ALNY) annual income statement — 24-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 |
|---|
| Sales/Revenue | 5.01B | 3.71B | 2.25B | 1.83B | 1.04B | 844.29M | 492.85M | 219.75M | 74.91M | 89.91M | 47.16M | 41.1M | 50.56M | 47.17M | 66.72M | 82.76M | 100.04M | 100.53M | 96.16M | 50.9M | 26.93M | 5.72M | 4.28M | 176K | 0 |
| Revenue Growth % | 56.17% | 65.19% | 22.97% | 76.23% | 22.88% | 71.31% | 124.28% | 193.36% | -16.69% | 90.66% | 14.75% | -18.72% | 7.2% | -29.31% | -19.37% | -17.28% | -0.49% | 4.54% | 88.94% | 89% | 371.13% | 33.61% | 2330.68% | - | - |
| Cost of Goods Sold | 1.14B | 677.17M | 323.37M | 310.41M | 168.82M | 140.14M | 78.05M | 25.06M | 1.8M | 13.37M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | 18.23% | 14.38% | 16.98% | 16.27% | 16.6% | 15.84% | 11.4% | 2.41% | 14.87% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 3.87B | 3.04B | 1.92B | 1.52B | 868.6M | 704.14M | 414.8M | 194.69M | 73.11M | 76.55M | 47.16M | 41.1M | 50.56M | 47.17M | 66.72M | 82.76M | 100.04M | 100.53M | 96.16M | 50.9M | 26.93M | 5.72M | 4.28M | 176K | 0 |
| Gross Margin % | 77.28% | 81.77% | 85.62% | 83.02% | 83.73% | 83.4% | 84.16% | 88.6% | 97.59% | 85.13% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | - |
| Gross Profit Growth % | - | 57.76% | 26.81% | 74.75% | 23.36% | 69.75% | 113.06% | 166.31% | -4.49% | 62.31% | 14.75% | -18.72% | 7.2% | -29.31% | -19.37% | -17.28% | -0.49% | 4.54% | 88.94% | 89% | 371.13% | 33.61% | 2330.68% | - | - |
| Operating Expenses | 2.9B | 2.54B | 2.1B | 1.8B | 1.65B | 1.41B | 1.24B | 1.13B | 887.78M | 590M | 471.75M | 337.11M | 234.78M | 140.11M | 131.18M | 137.57M | 144.11M | 148.64M | 124M | 144.07M | 66.43M | 49.19M | 36.54M | 20.62M | 4.22M |
| OpEx % of Revenue | - | 68.26% | 93.48% | 98.46% | 159.4% | 167.34% | 252.25% | 516.1% | 1185.16% | 656.2% | 1000.33% | 820.27% | 464.34% | 297.05% | 196.6% | 166.24% | 144.05% | 147.86% | 128.95% | 283.07% | 246.68% | 860.53% | 854.18% | 11718.18% | - |
| Selling, General & Admin | 1.34B | 1.21B | 975.53M | 795.65M | 770.66M | 620.64M | 588.42M | 479M | 382.36M | 199.37M | 89.35M | 60.61M | 44.53M | 27.15M | 44.61M | 38.28M | 37.73M | 39.91M | 27.11M | 23.39M | 16.63M | 13.87M | 11.94M | 7.53M | 880K |
| SG&A % of Revenue | - | 32.6% | 43.39% | 43.52% | 74.29% | 73.51% | 119.39% | 217.98% | 510.44% | 221.73% | 189.47% | 147.48% | 88.06% | 57.57% | 66.86% | 46.26% | 37.71% | 39.7% | 28.2% | 45.95% | 61.76% | 242.63% | 279.08% | 4276.7% | - |
| Research & Development | 1.56B | 1.32B | 1.13B | 1B | 883.01M | 792.16M | 654.82M | 655.11M | 505.42M | 390.63M | 382.39M | 276.5M | 190.25M | 112.96M | 86.57M | 99.3M | 106.38M | 108.73M | 96.88M | 120.69M | 49.8M | 35.32M | 24.6M | 13.1M | 3.34M |
| R&D % of Revenue | - | 35.66% | 50.09% | 54.94% | 85.12% | 93.83% | 132.86% | 298.12% | 674.72% | 434.46% | 810.86% | 672.79% | 376.28% | 239.48% | 129.74% | 119.98% | 106.34% | 108.15% | 100.75% | 237.12% | 184.92% | 617.9% | 575.11% | 7441.48% | - |
| Other Operating Expenses | 190K | 0 | 0 | 0 | 0 | -2.05M | 0 | 0 | 4.17M | -3.02M | 0 | 76K | 1.82M | -47K | 331K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | 977.59M | 501.58M | -176.88M | -282.18M | -785.07M | -708.65M | -828.44M | -939.43M | -814.67M | -500.09M | -424.59M | -296.01M | -404.98M | -92.94M | -129.46M | -54.82M | -44.07M | -48.11M | -27.84M | -93.18M | -39.5M | -43.47M | -32.26M | -25.06M | -4.22M |
| Operating Margin % | 19.5% | 13.51% | -7.87% | -15.43% | -75.68% | -83.94% | -168.09% | -427.5% | -1087.56% | -556.2% | -900.33% | -720.27% | -800.97% | -197.05% | -194.01% | -66.24% | -44.05% | -47.86% | -28.95% | -183.07% | -146.68% | -760.53% | -754.18% | -14236.93% | - |
| Operating Income Growth % | - | 383.56% | 37.31% | 64.06% | -10.78% | 14.46% | 11.81% | -15.31% | -62.91% | -17.78% | -43.44% | 26.91% | -335.73% | 28.21% | -136.16% | -24.39% | 8.4% | -72.84% | 70.13% | -135.89% | 9.13% | -34.74% | -28.76% | -493.49% | - |
| EBITDA | 1.03B | 557.24M | -120.22M | -228.12M | -740.6M | -661.09M | -754M | -885.06M | -808.24M | -486.72M | -409.46M | -276.96M | -393.05M | -82.71M | -120.42M | -49.69M | -39.13M | -42.12M | -22.11M | -89.09M | -35.69M | -40.35M | -29.82M | -24.22M | -4.19M |
| EBITDA Margin % | 20.61% | 15% | -5.35% | -12.48% | -71.39% | -78.3% | -152.99% | -402.76% | -1078.97% | -541.33% | -868.25% | -673.91% | -777.39% | -175.36% | -180.47% | -60.05% | -39.11% | -41.9% | -22.99% | -175.05% | -132.51% | -705.97% | -697.05% | -13760.8% | - |
| EBITDA Growth % | 221.79% | 563.53% | 47.3% | 69.2% | -12.03% | 12.32% | 14.81% | -9.51% | -66.06% | -18.87% | -47.84% | 29.54% | -375.2% | 31.31% | -142.33% | -27% | 7.1% | -90.51% | 75.18% | -149.66% | 11.57% | -35.32% | -23.13% | -478.57% | - |
| D&A (Non-Cash Add-back) | 55.43M | 55.66M | 56.67M | 54.05M | 44.47M | 47.57M | 74.44M | 54.37M | 6.43M | 13.37M | 15.13M | 19.05M | 11.93M | 10.23M | 9.04M | 5.13M | 4.94M | 5.99M | 5.73M | 4.08M | 3.81M | 3.12M | 2.44M | 838K | 36K |
| EBIT | 1.19B | 575.78M | -235.52M | -312.3M | -971.02M | -709.12M | -771.1M | -885.25M | -760.67M | -500.09M | -424.59M | -296.01M | -184.21M | -92.94M | -63.57M | -57.65M | -43.74M | -47.01M | -24.66M | -79.14M | -39.5M | -43.47M | -32.26M | -20.45M | -4.22M |
| Net Interest Income | -252.73M | -141.16M | -19.87M | -25.66M | -131.16M | -141.44M | -72.69M | 33.45M | 29.26M | 12.24M | 8.31M | 5.86M | 2.56M | 1.07M | 977K | 1.21M | 2.31M | 5.38M | 13.54M | 14.31M | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 112.31M | 111.47M | 121.99M | 95.56M | 24.81M | 1.58M | 11.81M | 33.45M | 29.26M | 12.24M | 8.31M | 5.86M | 2.56M | 1.07M | 977K | 1.21M | 2.31M | 5.38M | 14.41M | 15.39M | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 365.05M | 252.63M | 141.86M | 121.22M | 155.97M | 143.02M | 84.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 872K | 1.08M | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -121.19M | -178.43M | -200.49M | -151.34M | -341.92M | -143.49M | -27.16M | 54.18M | 54M | 9.21M | 14.48M | 5.93M | 4.38M | 1.02M | 12.87M | -2.83M | 1.07M | 1.1M | 2.31M | 12.96M | 4.89M | 558K | -390K | -4.64M | 0 |
| Pretax Income | 856.41M | 323.15M | -377.38M | -433.52M | -1.13B | -852.14M | -855.6M | -885.25M | -760.67M | -490.87M | -410.11M | -290.07M | -400.6M | -91.92M | -116.59M | -57.65M | -43M | -47.01M | -25.53M | -80.22M | -34.61M | -42.91M | -35.37M | -29.69M | 0 |
| Pretax Margin % | 17.08% | 8.7% | -16.79% | -23.71% | -108.63% | -100.93% | -173.6% | -402.85% | -1015.48% | -545.95% | -869.63% | -705.83% | -792.32% | -194.88% | -174.73% | -69.66% | -42.98% | -46.76% | -26.55% | -157.61% | -128.51% | -750.77% | -826.72% | -16871.59% | - |
| Income Tax | -1.9B | 9.4M | -99.22M | 6.72M | 4.16M | 680K | 2.68M | 863K | 823K | 0 | 0 | 0 | -40.21M | -2.69M | -10.57M | 0 | 514K | 582K | 719K | 5.25M | 0 | 0 | 390K | -4.58M | -86K |
| Effective Tax Rate % | -221.76% | 2.91% | 26.29% | -1.55% | -0.37% | -0.08% | -0.31% | -0.1% | -0.11% | 0% | 0% | 0% | 10.04% | 2.93% | 9.07% | 0% | -1.2% | -1.24% | -2.82% | -6.54% | 0% | 0% | -1.1% | 15.44% | - |
| Net Income | 2.72B | 313.75M | -278.16M | -440.24M | -1.13B | -852.82M | -858.28M | -886.12M | -761.5M | -490.87M | -410.11M | -290.07M | -360.39M | -89.22M | -106.01M | -57.65M | -43.52M | -47.59M | -26.25M | -85.47M | -34.61M | -42.91M | -32.65M | -25.03M | -4.14M |
| Net Margin % | 54.34% | 8.45% | -12.37% | -24.08% | -109.04% | -101.01% | -174.15% | -403.24% | -1016.58% | -545.95% | -869.63% | -705.83% | -712.79% | -189.17% | -158.88% | -69.66% | -43.5% | -47.34% | -27.3% | -167.92% | -128.51% | -750.77% | -763.3% | -14223.3% | - |
| Net Income Growth % | 6153.27% | 212.79% | 36.82% | 61.08% | -32.64% | 0.64% | 3.14% | -16.36% | -55.13% | -19.69% | -41.38% | 19.51% | -303.92% | 15.84% | -83.9% | -32.48% | 8.56% | -81.3% | 69.29% | -146.95% | 19.36% | -31.42% | -30.44% | -505.25% | - |
| Net Income (Continuing) | 2.76B | 313.75M | -278.16M | -440.24M | -1.13B | -852.82M | -858.28M | -886.12M | -761.5M | -490.87M | -410.11M | -290.07M | -360.39M | -89.22M | -106.01M | -57.65M | -43.52M | -47.59M | -26.25M | -85.47M | -34.61M | -42.91M | -32.65M | -25.03M | -4.14M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 19.74 | 2.33 | -2.18 | -3.52 | -9.30 | -7.20 | -7.46 | -8.11 | -7.57 | -5.42 | -4.79 | -3.45 | -4.85 | -1.45 | -2.11 | -1.36 | -1.04 | -1.14 | -0.64 | -2.21 | -1.09 | -1.96 | -2.75 | -26.56 | -12.48 |
| EPS Growth % | 8150% | 206.88% | 38.07% | 62.15% | -29.17% | 3.49% | 8.01% | -7.13% | -39.67% | -13.15% | -38.84% | 28.87% | -234.48% | 31.28% | -55.15% | -30.77% | 8.77% | -78.13% | 71.04% | -102.75% | 44.39% | 28.73% | 89.65% | -112.82% | - |
| EPS (Basic) | - | 2.39 | -2.18 | -3.52 | -9.30 | -7.20 | -7.46 | -8.11 | -7.57 | -5.42 | -4.79 | -3.45 | -4.85 | -1.45 | -2.11 | -1.36 | -1.04 | -1.14 | -0.64 | -2.21 | -1.09 | -1.96 | -2.75 | -26.56 | -12.48 |
| Diluted Shares Outstanding | 138.04M | 134.68M | 127.65M | 124.91M | 121.69M | 118.45M | 114.99M | 109.26M | 100.59M | 90.55M | 85.6M | 83.99M | 74.28M | 61.55M | 50.29M | 42.41M | 42.04M | 41.63M | 41.08M | 38.66M | 31.89M | 21.95M | 11.89M | 942.66K | 331.34K |
| Basic Shares Outstanding | 133.83M | 131M | 127.65M | 124.91M | 121.69M | 118.45M | 114.99M | 109.26M | 100.59M | 90.55M | 85.6M | 83.99M | 74.28M | 61.55M | 50.29M | 42.41M | 42.04M | 41.63M | 41.08M | 38.66M | 31.89M | 21.95M | 11.89M | 942.66K | 331.34K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying ALNY stock.
For fiscal year 2025, Alnylam Pharmaceuticals, Inc. (ALNY) reported total revenue of $3.71B.
Alnylam Pharmaceuticals, Inc. (ALNY) is profitable, generating $313.7M in net income for the fiscal year ending 2025 with a net profit margin of 8.4%.
Alnylam Pharmaceuticals, Inc. (ALNY) reported an operating income of $501.6M, resulting in an operating profit margin of 13.5%. This margin reflects the operational efficiency of the business before interest and taxes.
Alnylam Pharmaceuticals, Inc. (ALNY) generated $3.04B in gross profit for the year, representing a gross profit margin of 81.8%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Leverage and pipeline funding dependence
Metrics are mathematically derived from official filings.
Revenue Compounding Driven by Commercial Franchises
Based on reported quarterly figures, ALNY's revenue climbed from roughly $594M in 2025Q1 to about $1.5B in 2026Q3, a trajectory that reflects a shift from collaboration-driven income toward recurring product sales that warrant durability scrutiny.
The revenue ramp is substantial, but the quarterly pattern shows lumpiness, with 2026Q3 spiking on what appears to be partner milestone or non-cash collaboration recognition rather than purely patient-driven demand. Investors should separate the run-rate of Amvuttra and Onpattro from one-time milestone income before extrapolating the growth rate. The durability of the top line depends on whether ATTR-cardiomyopathy new patient starts can sustain volume gains as the polyneuropathy base matures.
High Gross Margin Masks Operating Volatility
Reported gross margins near 75% to 88% across the period indicate strong product-level economics for ALNY, yet operating margin swung from roughly -17.7% to 29.5%, showing that gross profit strength has not consistently translated into bottom-line stability.
The gross margin profile is consistent with a specialized oligonucleotide franchise carrying low variable cost, which supports the platform thesis. However, the operating margin volatility suggests that R&D and SG&A absorb most incremental gross profit, leaving earnings highly sensitive to revenue timing. Margin durability will therefore hinge on whether recent operating profitability reflects structural leverage or simply a favorable milestone quarter.
Operating Leverage Emerging but Unproven
Operating income turned positive in several recent quarters, with 2026Q3 reaching roughly $345.8M against SG&A of about $342.0M, suggesting that operating expenses are beginning to be absorbed by gross profit growth in reported figures.
The fixed-cost base in R&D of roughly $364M to $413M per quarter remains large relative to operating income, so leverage is real only when revenue sustains above that threshold. Based on reported figures, SG&A has stabilized near $320M to $350M while revenue scaled, which is a constructive sign of overhead discipline. Investors should monitor whether this relationship holds through quarters where milestone income is absent.
Net Income Inflated by Non-Operating Items
Reported net income of $2.2B in 2026Q3 far exceeds operating income of $345.8M, and as reported in financial statements, this gap suggests that non-operating or tax-related items are driving EPS of $15.72 rather than core operations.
A net margin of 148.6% against an operating margin of 23.7% indicates that the headline earnings figure is not representative of recurring profitability. Stock-based compensation of roughly $70M to $110M per quarter also weighs on GAAP earnings quality and signals a meaningful non-cash cost. Analysts should normalize EPS for these items before comparing the period to the operating trend.
R&D Intensity Dominates the Cost Base
R&D expense held in a band of roughly $265M to $413M per quarter, against COGS that remained modest at about $67M to $361M, indicating that ALNY's cost structure is driven by pipeline investment rather than manufacturing scale.
The R&D line is the dominant cost driver, reflecting the expansion into large-population indications such as hypertension, which requires costlier late-stage trials. Management's ability to keep SG&A relatively flat while revenue rose is a meaningful expense discipline signal in reported figures. The cost structure implies that continued pipeline spending will keep operating margins sensitive to any slowdown in product revenue.
Milestone-Dependent Earnings Undermine the Narrative
Quarterly results show revenue and net income swings that may indicate partner milestones and non-cash collaboration income are supporting the headline growth rate rather than purely recurring product demand.
Short-side scrutiny would focus on the gap between 2026Q3 net income of $2.2B and a far smaller operating result, which may suggest earnings are not representative of underlying profitability. Elevated debt-to-equity of 1.62 alongside negative prior-period operating results warrants further investigation into how pipeline funding is sustained. If milestone income normalizes, the reported growth rate could decelerate sharply, a risk investors should weigh against the platform premium the market appears to assign.